



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Christy Stevens, OD
Director of Clinical Affairs
Summit Autonomous Corporation
2501 Discovery Drive
Orlando, FL 32826

SEP 22 2000

Re: P970043/S7
LADARVision® Excimer Laser System
Filed: October 13, 1999
Amended: November 10 and December 7, 1999; January 18 and 31, February 22,
March 3, April 18, June 1, 6 and 30, July 18, and September 5, 2000

Dear Dr. Stevens:

The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement for the LADARVision® Excimer Laser System. The device is indicated for laser in-situ keratomileusis (LASIK) treatments:

- for the reduction or elimination of refractive error of less than or equal to +6.00D of sphere and -6.00D of cylinder at the spectacle plane (hyperopia with or without astigmatism and mixed astigmatism);
- in subjects with documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.50D for corrections up to +6.00D SE; and,
- in subjects who are 21 years of age or older.

We are pleased to inform you that the PMA supplement is approved subject to the conditions described below and in the "Conditions of Approval" (enclosed). You may begin commercial use and treatment with this device on patients who fulfill the above stated indications after you submit an amendment to this PMA supplement submission with copies of all approved labeling in final printed form.

The sale, distribution, and use of this device (LADARVision® Excimer Laser System) are restricted to prescription use in accordance with 21 CFR 801.109 within the meaning of section 520(e) of the Federal Food, Drug, and Cosmetic Act (the act) under the authority of section 515(d)(1)(B)(ii) of the act. FDA has also determined that, to ensure the safe and

effective use of the device, the device is further restricted within the meaning of section 520(e) under the authority of section 515(d)(1)(B)(ii), (1) insofar as the labeling specify the requirements that apply to the training of practitioners who may use the device as approved in this order and (2) insofar as the sale, distribution, and use must not violate sections 502(q) and (r) of the act.

These restrictions on the use, labeling, promotion, and advertising of the device are applicable to you, as well as any device purchasers and users. You must notify the purchasers and users of these restrictions and include them in your training programs.

1. Only licensed practitioners who are experienced in the medical management and surgical treatment of the cornea, who have been trained in system calibration and operation to perform laser refractive surgery (i.e., LASIK) for hyperopia, hyperopic astigmatism or mixed astigmatism, may use the device as approved in this order.
2. In advance of surgery, all prospective patients must receive the Patient Information Booklet (as described in your final submission to this PMA supplement) from their treatment provider.
3. Prior to undergoing surgery, prospective patients must be informed of the alternatives for correcting their hyperopia, hyperopic astigmatism, and/or mixed astigmatism including eyeglasses, contact lenses and other refractive surgeries.
4. Comparison of the safety and effectiveness of this laser with any other method of refractive correction in the promotion and advertising materials is prohibited. This prohibition is based on the fact that the data submitted for PMA supplement approval of the LADARVision® Excimer Laser System do not compare the clinical outcome of this device with any other method of refractive correction. Such comparisons of safety and effectiveness may be misleading and could misbrand your laser in accordance with section 502(a) of the act. All promotion and advertising for this device must include the following information on indications, risks and benefits:
 - a. Approval of the premarket approval application supplement is for the LADARVision® Excimer Laser System to perform laser in-situ keratomileusis (LASIK) treatments for the reduction or elimination of refractive error of less than or equal to +6.00D of sphere and -6.00D of cylinder at the spectacle plane (hyperopia with or without astigmatism and mixed astigmatism); in subjects with documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.50D for corrections up to +6.00D SE; and, in subjects who are 21 years of age or older.
 - b. LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), or laser thermal keratoplasty (LTK).

- c. Approval of the application is based on a clinical trial of 360 eyes: 152 eyes were treated for hyperopia, 143 for astigmatic hyperopia, and 65 for mixed astigmatism. Of all eyes treated, 324 eyes were available for analysis at 6 months, and 265 eyes were followed for 9 months. Accountability at 3 months was 95.6%, at 6 months was 95.3%, and at 9 months was 90.4%.
- d. The analysis of refractive data at the 6 month stability time point found that 113 (93.4%) hyperopic eyes were 20/40 or better and 59 eyes (48.8%) were 20/20 or better without spectacles or contact lenses. In the astigmatic hyperopic eye group, 100 eyes (90.9%) were 20/40 or better and 41 eyes (37.3%) were 20/20 or better without spectacles or contact lenses. In the mixed astigmatic eye group, 50 eyes (92.6%) were 20/40 or better and 25 (46.3%) were 20/20 or better without spectacles or contact lenses.
- e. The study showed that at the 6 month stability time point, there was a loss of 2 lines of the best vision that can be obtained with spectacles in 5 (3.5%) hyperopic eyes, 7 (5.8%) hyperopic astigmatic eyes, and 1 (1.9%) mixed astigmatic eye. Most of the other adverse events and complications occurred with low frequencies (< 1%). The four events with $\geq 1\%$ rate were double/ghost images (1.5%), epithelium in the interface (1.5%), interface debris (1.5%) and superficial punctate keratitis (3.1%).
- f. Long term (beyond 9 months) risks of LASIK for hyperopia, hyperopic astigmatism, and mixed astigmatism have not been studied.
- g. Note that the complete name for the device, approved with this order, is “the LADARVision® Excimer Laser System for laser in-situ keratomileusis (LASIK) treatments of hyperopia with or without astigmatism and mixed astigmatism of less than or equal +6.00D of sphere and -6.00D of cylinder at the spectacle plane.” An acceptable alternate version of this official name is “LASIK laser correction for farsightedness with or without astigmatism.”

CDRH will notify the public of its decision to approve your PMA by making available a summary of the safety and effectiveness data upon which the approval is based. The information will be available on the FDA CDRH Internet HomePage located at <http://www.fda.gov/cdrh/pmapage.html>. Written requests for this information can also be made to the Dockets Management Branch, (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The written request should include the PMA number or docket number. Within 30 days from the date that this information is placed on the Internet, any interested person may seek review of this decision by requesting an opportunity for administrative review, either through a hearing or review by an independent advisory committee, under section 515(g) of the Federal Food, Drug, and Cosmetic Act (the act).

In addition to the postapproval requirements in the enclosure, the following information must also be submitted to the Agency. You must immediately submit reports to FDA CDRH's Office of Compliance at the address below of any instances of device tampering.

OC/Division of Enforcement (HFZ-331)
Center for Devices and Radiological Health
Food and Drug Administration
2098 Gaither Road
Rockville, Maryland 20850

Failure to comply with the conditions of approval invalidates this approval order. Commercial distribution of a device that is not in compliance with these conditions is a violation of the act.

All required documents should be submitted in triplicate, unless otherwise specified, to the address below and should reference the above PMA number to facilitate processing.

PMA Document Mail Center (HFZ-401)
Center for Devices and Radiological Health
Food and Drug Administration
9200 Corporate Blvd.
Rockville, Maryland 20850

If you have any questions concerning this approval order, please contact Quynh Hoang at (301) 594-2018.

Sincerely yours,



Daniel G. Schultz, M.D.
Captain, USPHS
Deputy Director for Clinical and Review Policy
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure:
Conditions of Approval

Issued: 3-4-98

CONDITIONS OF APPROVAL

APPROVED LABELING. As soon as possible, and before commercial distribution of your device, submit three copies of an amendment to this PMA submission with copies of all approved labeling in final printed form to the PMA Document Mail Center (HFZ-401), Center for Devices and Radiological Health, Food and Drug Administration (FDA), 9200 Corporate Blvd., Rockville, Maryland 20850.

ADVERTISEMENT. No advertisement or other descriptive printed material issued by the applicant or private label distributor with respect to this device shall recommend or imply that the device may be used for any use that is not included in the FDA approved labeling for the device. If the FDA approval order has restricted the sale, distribution and use of the device to prescription use in accordance with 21 CFR 801.109 and specified that this restriction is being imposed in accordance with the provisions of section 520(e) of the act under the authority of section 515(d)(1)(B)(ii) of the act, all advertisements and other descriptive printed material issued by the applicant or distributor with respect to the device shall include a brief statement of the intended uses of the device and relevant warnings, precautions, side effects and contraindications.

PREMARKET APPROVAL APPLICATION (PMA) SUPPLEMENT. Before making any change affecting the safety or effectiveness of the device, submit a PMA supplement for review and approval by FDA unless the change is of a type for which a "Special PMA Supplement-Changes Being Effectuated" is permitted under 21 CFR 814.39(d) or an alternate submission is permitted in accordance with 21 CFR 814.39(e). A PMA supplement or alternate submission shall comply with applicable requirements under 21 CFR 814.39 of the final rule for Premarket Approval of Medical Devices.

All situations which require a PMA supplement cannot be briefly summarized, please consult the PMA regulation for further guidance. The guidance provided below is only for several key instances.

A PMA supplement must be submitted when unanticipated adverse effects, increases in the incidence of anticipated adverse effects, or device failures necessitate a labeling, manufacturing, or device modification.

A PMA supplement must be submitted if the device is to be modified and the modified device should be subjected to animal or laboratory or clinical testing designed to determine if the modified device remains safe and effective.

A "Special PMA Supplement - Changes Being Effectuated" is limited to the labeling, quality control and manufacturing process changes specified under 21 CFR 814.39(d)(2). It allows for the addition of, but not the replacement of previously approved, quality control specifications and test methods. These changes may be implemented before FDA approval upon acknowledgment by FDA that the submission is being processed as a "Special PMA Supplement - Changes Being Effectuated." This acknowledgment is in addition to that issued by the PMA Document Mail Center for all PMA supplements submitted. This procedure is not applicable to changes in device design, composition, specifications, circuitry, software or energy source.

Alternate submissions permitted under 21 CFR 814.39(e) apply to changes that otherwise require approval of a PMA supplement before implementation of the change and include the use of a 30-day PMA supplement or annual postapproval report. FDA must have previously indicated in an advisory opinion to the affected industry or in correspondence with the applicant that the alternate submission is permitted for the change. Before such can occur, FDA and the PMA applicant(s) involved must agree upon any needed testing protocol, test results, reporting format, information to be reported, and the alternate submission to be used.

POSTAPPROVAL REPORTS. Continued approval of this PMA is contingent upon the submission of postapproval reports required under 21 CFR 814.84 at intervals of 1 year from the date of approval of the original PMA. Postapproval reports for supplements approved under the original PMA, if applicable, are to be included in the next and subsequent annual reports for the original PMA unless specified otherwise in the approval order for the PMA supplement. Two copies identified as "Annual Report" and bearing the applicable PMA reference number are to be submitted to the PMA Document Mail Center (HFZ-401), Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, Maryland 20850. The postapproval report shall indicate the beginning and ending date of the period covered by the report and shall include the following information required by 21 CFR 814.84:

(1) Identification of changes described in 21 CFR 814.39(a) and changes required to be reported to FDA under 21 CFR 814.39(b).

(2) Bibliography and summary of the following information not previously submitted as part of the PMA and that is known to or reasonably should be known to the applicant:

(a) unpublished reports of data from any clinical investigations or nonclinical laboratory studies involving the device or related devices ("related" devices include devices which are the same or substantially similar to the applicant's device); and

(b) reports in the scientific literature concerning the device.

If, after reviewing the bibliography and summary, FDA concludes that agency review of one or more of the above reports is required, the applicant shall submit two copies of each identified report when so notified by FDA.

ADVERSE REACTION AND DEVICE DEFECT REPORTING. As provided by 21 CFR 814.82(a)(9), FDA has determined that in order to provide continued reasonable assurance of the safety and effectiveness of the device, the applicant shall submit 3 copies of a written report identified, as applicable, as an "Adverse Reaction Report" or "Device Defect Report" to the PMA Document Mail Center (HFZ-401), Center for Devices and Radiological Health, Food and Drug Administration, 9200 Corporate Blvd., Rockville, Maryland 20850 within 10 days after the applicant receives or has knowledge of information concerning:

(1) A mix-up of the device or its labeling with another article.

(2) Any adverse reaction, side effect, injury, toxicity, or sensitivity reaction that is attributable to the device and
(a) has not been addressed by the device's labeling or

(b) has been addressed by the device's labeling, but is occurring with unexpected severity or frequency.

(3) Any significant chemical, physical or other change or deterioration in the device or any failure of the device to meet the specifications established in the approved PMA that could not cause or contribute to death or serious injury but are not correctable by adjustments or other maintenance procedures described in the approved labeling. The report shall include a discussion of the applicant's assessment of the change, deterioration or failure and any proposed or implemented corrective action by the applicant. When such events are correctable by adjustments or other maintenance procedures described in the approved labeling, all such events known to the applicant shall be included in the Annual Report described under "Postapproval Reports" above unless specified otherwise in the conditions of approval to this PMA. This postapproval report shall appropriately categorize these events and include the number of reported and otherwise known instances of each category during the reporting period. Additional information regarding the events discussed above shall be submitted by the applicant when determined by FDA to be necessary to provide continued reasonable assurance of the safety and effectiveness of the device for its intended use.

REPORTING UNDER THE MEDICAL DEVICE REPORTING (MDR) REGULATION. The Medical Device Reporting (MDR) Regulation became effective on December 13, 1984. This regulation was replaced by the reporting requirements of the Safe Medical Devices Act of 1990 which became effective July 31, 1996 and requires that all manufacturers and importers of medical devices, including in vitro diagnostic devices, report to the FDA whenever they receive or otherwise become aware of information, from any source, that reasonably suggests that a device marketed by the manufacturer or importer:

- (1) May have caused or contributed to a death or serious injury; or
- (2) Has malfunctioned and such device or similar device marketed by the manufacturer or importer would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.

The same events subject to reporting under the MDR Regulation may also be subject to the above "Adverse Reaction and Device Defect Reporting" requirements in the "Conditions of Approval" for this PMA. FDA has determined that such duplicative reporting is unnecessary. Whenever an event involving a device is subject to reporting under both the MDR Regulation and the "Conditions of Approval" for a PMA, the manufacturer shall submit the appropriate reports required by the MDR Regulation within the time frames as identified in 21 CFR 803.10(c) using FDA Form 3500A, i.e., 30 days after becoming aware of a reportable death, serious injury, or malfunction as described in 21 CFR 803.50 and 21 CFR 803.52 and 5 days after becoming aware that a reportable MDR event requires remedial action to prevent an unreasonable risk of substantial harm to the public health. The manufacturer is responsible for submitting a baseline report on FDA Form 3417 for a device when the device model is first reported under 21 CFR 803.50. This baseline report is to include the PMA reference number. Any written report and its envelope is to be specifically identified, e.g., "Manufacturer Report," "5-Day Report," "Baseline Report," etc.

Any written report is to be submitted to:

Food and Drug Administration
Center for Devices and Radiological Health
Medical Device Reporting
PO Box 3002
Rockville, Maryland 20847-3002

Copies of the MDR Regulation (FOD # 336&1336) and FDA publications entitled "An Overview of the Medical Device Reporting Regulation" (FOD # 509) and "Medical Device Reporting for Manufacturers" (FOD #987) are available on the CDRH WWW Home Page. They are also available through CDRH's Fact-On-Demand (F-O-D) at 800-899-0381. Written requests for information can be made by sending a facsimile to CDRH's Division of Small Manufacturers Assistance (DSMA) at 301-443-8818.